InterMune: Layer upon layer By Steve Edelson
Staff Writer

Armed with a marketed product, InterMune Pharmaceuticals Inc. believes it can become profitable in the next four years by adding indications to its Actimmune gamma interferon. The product, initially developed by Genentech Inc., was approved in 1991 to treat chronic granulomatous disease (CGD) and the company plans to gain additional approvals to treat multiple-drug resistant strains of tuberculosis, fungal infections and osteopetrosis.